KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Cash (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Change in Cash data on record, last reported at $244.7 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 139.18% year-over-year to $244.7 million; the TTM value through Dec 2025 reached -$119.3 million, down 106.24%, while the annual FY2025 figure was -$119.3 million, 106.24% down from the prior year.
  • Change in Cash reached $244.7 million in Q4 2025 per EW's latest filing, up from -$595.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $2.0 billion in Q3 2024 and bottomed at -$652.5 million in Q4 2021.
  • Average Change in Cash over 5 years is $87.0 million, with a median of $119.4 million recorded in 2021.
  • Peak YoY movement for Change in Cash: crashed 482.25% in 2021, then surged 1905.38% in 2022.
  • A 5-year view of Change in Cash shows it stood at -$652.5 million in 2021, then grew by 26.57% to -$479.1 million in 2022, then soared by 44.5% to -$265.9 million in 2023, then tumbled by 134.9% to -$624.6 million in 2024, then soared by 139.18% to $244.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $244.7 million in Q4 2025, -$595.2 million in Q3 2025, and $141.2 million in Q2 2025.